By computing the percentage change between the last two years for the following: (numbers are in millions of dollars)

Johnson & Johnson and subsidiaries consolidated statements of earnings (Dollars and Shares in Millions Except Per Share Amounts) (Mote 1) 2023 2022 2021 Sales to customers 385,159 79,950 78,740 Cost of products sold Gross profit Selling, marketing and administrative expenses Research and development expense In-process research and development Impaiments Interest Income Interest expense, net of portion capitalized (Note 4) Other {income) expense, net Restructuring {(Mote 20) Eamings before provision for laxes on income Provision for laxes on income (Note B) Met eamings from continuing operations 26,553 58,606 21,512 15,085 313 {1,261) 772 6,634 489 15,062 1,736 13,326 24 506 55,304 20,246 14,135 783 (480) 276 B0 275 19,359 2,989 16,370 23,402 55,338 20,118 14,277 200 (53) 183 526 209 19,178 1,377 17,801 Met eamings from discontinued operations, net of tax (Mote 21) Net earnings 21,827 $35,153 1,571 17,941 3077 20,878 Net earnings per share (Notes 1 and 15) Continuing operations - basic Digcontinued operations - basic $5.26 $8.62 6.23 0.60 6.76 147 Total net earnings per share - basic Continuing operations - diluted $13.88 $5.20 6.83 614 7.93 6.66 Discontinued operations - diluted g 8.52 0.59 115